Horiba UK Medical has announced the publication of two studies evaluating the use of its Yumizen H500 haematology analyser for point-of-care testing (POCT) to enhance the care of oncology patients. With near-patient, full blood count results, patients undergoing chemotherapy can receive treatment without delay and greatly reduce their hospital/clinic exposure times.
The evaluation studies were performed by the Cardiff and Vale Health Board (CAVHB), University Hospital of Wales and the Spire Bushey Laboratory in London. Both studies demonstrated that the compact, easy-to-use analyser delivered key parameters at the point of care that showed exceptional correlation with larger laboratory-based haematology analysers. Blood samples from oncology patients may be abnormal, having low counts and atypical blood cells, therefore it is essential that near-patient testing does not compromise the clinical integrity of results.
Both studies found that in addition to speed and ease of use, the Yumizen H500’s functionality and audit systems fully adhere to ISO standards (15189:2012 and 22870:2016) with the same internal quality controls as larger analysers. This in turn ensured detailed, accurate results for timely and sound clinical decision-making.
